EGFR and non-small cell lung carcinoma: This neoantigen vaccine prevents recurrence for 25 months after treatment in four out of six high-risk melanoma patients.15 In NSCLC patients who have failed in multiple conventional therapies, personalized neoantigen peptide vaccination triggers specific T cell responses targeting EGFR mutations, including the relatively prevalent mutations L858R and T790M.